JBIO

Jade Biosciences, Inc.

Fundamental data last updated:November 18, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

 


VALUATION

P/E

-5.77

Market Cap ($M USD)

$1.01B

Forward P/E

-9.69

PEG

-2.29

PRICE TO SALES

0.00

PRICE TO BOOK

2.20

EV / EBITDA

-5.78

5-Year Average P/E

Free Cash Flow Yield

-12.24%

DCF Value

$2.74

Graham Number

N/A

Price to FCF

-8.17

EV to FCF

-7.30

Earnings Yield

-15.82%

FCF Yield

-12.24%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.51

Next Year EPS Growth Estimate

-$2.95

Next Year Revenue Growth Estimate

$0.00

Return on Equity (ROE)

-49.11%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00

Piotroski F-Score

2

Altman Z-Score

18.93

Return on Invested Capital (ROIC)

-37.39%

Current Ratio

14.93

Quick Ratio

14.93

Net Debt to EBITDA

0.68

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-2.02

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Jade Biosciences, Inc. significantly. With a DCF value far below its recent trading price, the stock appears overvalued. The negative Forward P/E and Earnings Yield suggest a lack of profitability, yet the Altman Z-score of 20.79 indicates financial stability, hinting at a paradox of safety amidst poor earnings. This biotech firm is not a typical value play, as its fundamentals reveal a complex picture of high risk and potential resilience.

AI Exposure / Tech Reliance

In the rapidly evolving biotech sector, Jade Biosciences is well-positioned to leverage AI and modern tech advancements. The industry’s inherent focus on innovation and research aligns with AI-driven drug discovery and personalized medicine. This adaptability could enhance their competitive edge in developing cutting-edge therapies.

The Bull Case

For the optimistic investor, Jade Biosciences offers a compelling narrative of potential growth. Despite a negative ROIC and FCF Yield, the company’s exceptionally low Debt/Equity ratio and robust Current Ratio suggest financial prudence and liquidity. The high Altman Z-score further underscores its financial health, while the consensus "Buy" rating reflects institutional confidence in its future prospects.

The Bear Case

However, the bear case is hard to ignore. The negative Price to FCF and Earnings Yield highlight severe cash flow issues, while the Price/Book ratio of 5.03 suggests overvaluation. Trading close to its 52-week high, the stock appears technically overextended. The Piotroski F-Score of 1 signals weak financial health, raising red flags about its operational efficiency and management quality.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$48.40

Institutional Ownership %

1-Year Beta

1.45

Insider Buying % (6 Mo)

Distance to 52-Week High

76.43%

Distance to 52-Week Low

40.08%

EARNINGS SURPRISE %

-19.42%

50-DAY SMA

$15.51

200-DAY SMA

$18.22

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.